Spots Global Cancer Trial Database for hormone refractory prostate cancer
Every month we try and update this database with for hormone refractory prostate cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer | NCT01560923 | Metastatic Pros... | Indoximod Sipuleucel-T Placebo | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors | NCT00514267 | Prostate Cancer Tumors | YM 155 Docetaxel Prednisone | 18 Years - | Astellas Pharma Inc | |
| BAY88-8223, Does Response Study in HRPC Patients | NCT00667199 | Hormone Refract... Bone Metastases | Radium-223 dich... | 40 Years - | Bayer | |
| A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients | NCT02691975 | Hormone Refract... Metastatic Pros... | SHR3680 | 18 Years - 80 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Molecular Phenotype Changes and Personalized Treatment for CRPC | NCT02208583 | Hormone Refract... | Docetaxel & Pre... DP & Targeted d... cisplatin & Eto... EP & Targeted d... | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | NCT00887198 | Prostate Cancer | Abiraterone ace... Placebo Prednisone | 18 Years - | Janssen Research & Development, LLC | |
| Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases | NCT01516762 | Prostatic Neopl... | Radium-223 dich... | 18 Years - | Bayer | |
| A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer | NCT00525408 | Hormone Refract... | Mycobacterium w... Docetaxel | 18 Years - | Cadila Pharnmaceuticals | |
| A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer | NCT00215345 | Prostate Cancer | Taxotere Celecoxib | 18 Years - | Department of Veterans Affairs, New Jersey | |
| Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer | NCT00861471 | Prostate Cancer Prostatic Neopl... | Docetaxel Imatinib Mesyla... | 18 Years - | NYU Langone Health | |
| Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases | NCT01516762 | Prostatic Neopl... | Radium-223 dich... | 18 Years - | Bayer | |
| A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) | NCT00571675 | Hormone Refract... | AT-101, prednis... placebo, predni... | 18 Years - | Ascenta Therapeutics | |
| A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer | NCT00286806 | Hormone Refract... | AT-101 | 18 Years - | Ascenta Therapeutics | |
| Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) | NCT00450970 | Prostate Cancer | Oral Satraplati... | 18 Years - | Agennix | |
| Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy | NCT00133900 | Hormone Refract... Prostate Cancer | Phlebotomy | 18 Years - | Immunicon | |
| Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients | NCT00327288 | Non-small Cell ... Breast Cancer Prostate Cancer | imexon docetaxel | 18 Years - | AmpliMed Corporation | |
| Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone | NCT00493766 | Hormone Refract... | LBH589 | 18 Years - | Novartis | |
| Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer | NCT00795171 | Hormone Refract... | Docetaxel * Sun... Docetaxel Docetaxel | 18 Years - | Medical University of Vienna | |
| Radiotherapy vs Observation for CRPC | NCT01590498 | Hormone Refract... | - | Zhengzhou University | ||
| A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer | NCT00156884 | Hormone Refract... Bone Metastases | strontium-89 cisplatin | 18 Years - | AHS Cancer Control Alberta | |
| Efficacy and Safety Study of Xyotax to Treat Prostate Cancer | NCT00446836 | Prostatic Neopl... | Paclitaxel poly... | 18 Years - | The Methodist Hospital Research Institute | |
| A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients | NCT02691975 | Hormone Refract... Metastatic Pros... | SHR3680 | 18 Years - 80 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer | NCT00477529 | Hormone Refract... | ABI-008 | 18 Years - | Celgene | |
| Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer | NCT01215799 | Hormone Refract... | Bafetinib | 18 Years - | CytRx | |
| A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) | NCT00571675 | Hormone Refract... | AT-101, prednis... placebo, predni... | 18 Years - | Ascenta Therapeutics | |
| The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment | NCT02955082 | Hormone Refract... | Carboplatin | 18 Years - | Institute of Cancer Research, United Kingdom | |
| A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer | NCT00448734 | Hormone Refract... | Picoplatin docetaxel | 18 Years - | Poniard Pharmaceuticals | |
| Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen | NCT00069745 | Prostate Cancer Hormone Refract... | Satraplatin Prednisone | 18 Years - | Agennix | |
| A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer | NCT00479635 | Prostate Cancer | TPI 287 TPI 287 | 18 Years - | Cortice Biosciences, Inc. | |
| PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer | NCT02867345 | Hormone Refract... | PD-1 Knockout T... Cyclophosphamid... IL-2 | 45 Years - 85 Years | Peking University | |
| A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer | NCT00218205 | Prostate Cancer | Epirubicin Estramustine Ph... Celecoxib | 18 Years - | Department of Veterans Affairs, New Jersey | |
| Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228 | NCT00106301 | Carcinoma, Rena... Prostatic Neopl... | FK228 (romideps... | 18 Years - | Celgene | |
| PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC | NCT00313482 | Hormone Refract... | Sargramostim Docetaxel Prednisone | 18 Years - 90 Years | Veeda Oncology | |
| A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing | NCT00381173 | Breast Cancer Ovarian Cancer Prostate Cancer Colon Cancer Renal Cancer | Cyclophosphamid... | 18 Years - | Eisai Inc. | |
| Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel | NCT01260688 | Hormone Refract... Recurrent Prost... | cediranib malea... dasatinib | 18 Years - | National Cancer Institute (NCI) | |
| Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228 | NCT00106301 | Carcinoma, Rena... Prostatic Neopl... | FK228 (romideps... | 18 Years - | Celgene | |
| A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer | NCT00510718 | Prostate Cancer Hormone Refract... | MDV3100 | - | Pfizer | |
| Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer | NCT00918385 | Prostate Cancer | Nilutamide Dasatinib | 18 Years - | Duke University | |
| ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer | NCT00477529 | Hormone Refract... | ABI-008 | 18 Years - | Celgene | |
| Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors | NCT00511576 | Breast Cancer Lung Cancer Pulmonary Cance... Non-Small-Cell ... Prostate Cancer Prostatic Cance... Gastric Cancer Stomach Cancer | MGCD0103 & Doce... | 18 Years - | Mirati Therapeutics Inc. | |
| A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) | NCT00571675 | Hormone Refract... | AT-101, prednis... placebo, predni... | 18 Years - | Ascenta Therapeutics | |
| Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228 | NCT00106301 | Carcinoma, Rena... Prostatic Neopl... | FK228 (romideps... | 18 Years - | Celgene | |
| A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer | NCT00479635 | Prostate Cancer | TPI 287 TPI 287 | 18 Years - | Cortice Biosciences, Inc. | |
| Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients | NCT00411853 | Hormone Refract... | Fermented Wheat... | 18 Years - | Sheba Medical Center | |
| RNActive®-Derived Therapeutic Vaccine | NCT00906243 | Hormone Refract... | CV9103 | 18 Years - 75 Years | University of Florida | |
| Study Evaluating the Safety and Tolerability of L-377202 | NCT00987753 | Hormone Refract... Prostate Cancer | L-377202 | 18 Years - | University of Alabama at Birmingham | |
| A Long Term Safety Study With Atrasentan | NCT00127478 | Prostate Cancer Adenocarcinoma | Atrasentan | 18 Years - | Abbott | |
| An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors | NCT00514267 | Prostate Cancer Tumors | YM 155 Docetaxel Prednisone | 18 Years - | Astellas Pharma Inc | |
| A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy | NCT00473512 | Prostatic Neopl... | Abiraterone ace... Abiraterone ace... Dexamethasone | 18 Years - | Cougar Biotechnology, Inc. | |
| Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer | NCT00738673 | Prostate Cancer | degarelix | 18 Years - | Ferring Pharmaceuticals | |
| Efficacy and Safety Study of Xyotax to Treat Prostate Cancer | NCT00446836 | Prostatic Neopl... | Paclitaxel poly... | 18 Years - | The Methodist Hospital Research Institute | |
| Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer | NCT00861471 | Prostate Cancer Prostatic Neopl... | Docetaxel Imatinib Mesyla... | 18 Years - | NYU Langone Health | |
| Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer | NCT00448409 | Prostatic Neopl... | TroVax GM-CSF | 18 Years - | The Methodist Hospital Research Institute | |
| Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective. | NCT00043212 | Prostate Cancer | Dendritic cell ... | 18 Years - | Northwest Biotherapeutics | |
| Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy | NCT00407251 | Hormone Refract... | Patupilone | 18 Years - | British Columbia Cancer Agency | |
| BAY88-8223, Does Response Study in HRPC Patients | NCT00667199 | Hormone Refract... Bone Metastases | Radium-223 dich... | 40 Years - | Bayer | |
| A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | NCT01083615 | Castrate-Resist... Hormone Refract... | custirsen sodiu... isotonic, 0.9% ... docetaxel cabazitaxel prednisone | 18 Years - 99 Years | Achieve Life Sciences | |
| Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer | NCT01692483 | Prostate Neopla... | Abiraterone ace... Prednisone | 18 Years - | Janssen Pharmaceutica | |
| A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer | NCT00525408 | Hormone Refract... | Mycobacterium w... Docetaxel | 18 Years - | Cadila Pharnmaceuticals | |
| Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer | NCT00111618 | Prostate Cancer | AS1404 (DMXAA) | 18 Years - | Antisoma Research | |
| Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer | NCT00136526 | Prostate Cancer | Docetaxel and D... | 21 Years - 83 Years | University of Washington | |
| An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001 | NCT01664728 | Prostate Neopla... | Abiraterone ace... Glucocorticoid | 18 Years - | Janssen Research & Development, LLC | |
| Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases | NCT01618370 | Prostatic Neopl... | Radium-223 dich... | 18 Years - | Bayer | |
| Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases | NCT01618370 | Prostatic Neopl... | Radium-223 dich... | 18 Years - | Bayer | |
| Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer | NCT00286091 | Hormone Refract... | Denosumab Placebo | 18 Years - | Amgen | |
| A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases | NCT00699751 | Hormone Refract... Bone Metastases | Radium-223 dich... Placebo Best standard o... | 18 Years - | Bayer | |
| Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) | NCT00450970 | Prostate Cancer | Oral Satraplati... | 18 Years - | Agennix | |
| A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases | NCT00699751 | Hormone Refract... Bone Metastases | Radium-223 dich... Placebo Best standard o... | 18 Years - | Bayer | |
| RNActive®-Derived Therapeutic Vaccine | NCT00906243 | Hormone Refract... | CV9103 | 18 Years - 75 Years | University of Florida | |
| A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | NCT01083615 | Castrate-Resist... Hormone Refract... | custirsen sodiu... isotonic, 0.9% ... docetaxel cabazitaxel prednisone | 18 Years - 99 Years | Achieve Life Sciences | |
| Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | NCT00887198 | Prostate Cancer | Abiraterone ace... Placebo Prednisone | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer | NCT00286806 | Hormone Refract... | AT-101 | 18 Years - | Ascenta Therapeutics | |
| RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer | NCT00629525 | Hormone Refract... | RAD001 | 18 Years - | Duke University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
